Abstract
Non-alcoholic fatty liver disease (NAFLD) is considered as a common cause of chronic liver disease. It is potentially progressive towards non-alcoholic steatohepatitis (NASH), hepatic fibrosis, cirrhosis and its complications including hepatocellular carcinoma (HCC). So, the need for predictive factors of NAFLD is important. Among the different serum markers in NAFLD, serum uric acid (SUA) has emerged as a possible predictor of severity of liver damage. This observational cross sectional study was carried out involving 100 patients from the department of gastroenterology, BSMMU, Dhaka, with the intention to determine the association of serum uric acid (SUA) level with non-alcoholic fatty liver disease. Among them, 55 were having NAFLD; and 45 subjects without NAFLD were considered as control. The diagnosis of NAFLD was based on the guidelines for the assessment and management of NAFLD in the Asia-pacific region. Serum uric acid, liver enzymes, glycaemic status, serum lipid profile and anthropometric measurements were compared between NAFLD group & control. The mean age was found 41.34 + 10.88 years in both the groups. Male were 62% & female were 38% among the study population. Forty percent of the study subjects were overweight, 23% were obese and 37% had normal body weight. NAFLD patients had significantly higher serum uric level (6.9 + 0.89 mg/dl) in comparison to non-NAFLD group (4.3 +0.87 mg/dl). The study showed that serum uric acid level was significantly associated with NAFLD. Serum uric acid may be used as a useful additional marker to assess the risk of development of NAFLD in the clinical setting of metabolic syndrome. BSMMU J 2021; 14(4): 125-131
Highlights
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of pathological conditions including simple steatosis, nonalcoholic steatohepatitis (NASH) and cirrhosis influencing approximately 20-30% of the general population and its prevalence is increasing worldwide.[1]
The coexistence of NAFLD and T2DM is clinically important for the following reasons: 1) T2DM is an important predictor of development of hepatic fibrosis in patients with NAFLD (8) and 2) the presence of T2DM is pivotal with respect to increased risks of cardiovascular disorders and the development of hepatocellular carcinoma in the setting of NAFLD.[9,10]
Our study showed a clear association between NAFLD and serum uric acid level
Summary
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of pathological conditions including simple steatosis, nonalcoholic steatohepatitis (NASH) and cirrhosis influencing approximately 20-30% of the general population and its prevalence is increasing worldwide.[1]. Simple steatosis is generally a benign condition; NASH can progress to cirrhosis and liver failure[4] and the 5-year survival rate for individuals diagnosed with NASH is estimated to be only 67%.5. Patients with elevation of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT), high AST/ALT ratio and fatty changes on ultrasonography (USG) or computed tomography (CT) without a history of alcohol intake or positive hepatitis virus markers or autoantibodies can be suspected as having NAFLD.[6,7]. There is evidence that suggests elevated serum uric acid (SUA) is commonly associated with the development or progression of NAFLD.[11,12] The coexistence of NAFLD and T2DM is clinically important for the following reasons: 1) T2DM is an important predictor of development of hepatic fibrosis in patients with NAFLD (8) and 2) the presence of T2DM is pivotal with respect to increased risks of cardiovascular disorders and the development of hepatocellular carcinoma in the setting of NAFLD.[9,10] There is evidence that suggests elevated serum uric acid (SUA) is commonly associated with the development or progression of NAFLD.[11,12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
